Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review
Research article published in Molecules (Basel, Switzerland) (2017)
Abstract
A rapid and accurate diagnosis in patients with suspected heparin-induced thrombocytopenia (HIT) is essential for patient management but remains challenging. Current HIT diagnosis ideally relies on a combination of clinical information, immunoassay and functional assay results. Platelet activation assays or functional assays detect HIT antibodies that are more clinically significant. Several functional assays have been developed and evaluated in the literature. They differ in the activation endpoint studied; the technique or technology used; the platelet donor selection; the platelet suspension (washed platelets, platelet rich plasma or whole blood); the patient sample (serum or plasma); and the heparin used (type and concentrations). Inconsistencies in controls performed and associated results interpretation are common. Thresholds and performances are determined differently among papers. Functional assays suffer from interlaboratory variability. This lack of standardization limits the evaluation and the accessibility of functional assays in laboratories. In the present article, we review all the current activation endpoints, techniques and methodologies of functional assays developed for HIT diagnosis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This review surveys the functional (platelet-activation) assays used to diagnose heparin-induced thrombocytopenia (HIT), detailing how they differ in endpoints, platelet sources, and methodology, and emphasizing that a lack of standardization and interlaboratory variability limit their accessibility. For the hirudotherapy evidence picture this matters as background on why heparin's immunologic complication, HIT, drives interest in non-heparin anticoagulants, including the direct thrombin inhibitor class to which the leech-derived molecule hirudin belongs. The caveat is significant: this is a methodological review of diagnostic assays that does not mention leeches, hirudin, or hirudotherapy, so it is purely supporting context, not evidence about leech-based treatment.
Citation
Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.
Minet et al. · Molecules (Basel, Switzerland), 2017
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026